FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4316038761> ?p ?o ?g. }

• W4316038761 endingPage "76" @default.
• W4316038761 startingPage "66" @default.
• W4316038761 abstract "Bone metastases (BM) in renal cell carcinoma (RCC) are associated with a poor prognosis based on retrospective studies evaluating antiangiogenic agents. Few data are available regarding immune checkpoint inhibitors (ICI) in patients with bone metastatic RCC. NIVOREN is a multicentre prospective study in which patients were treated with nivolumab after the failure of antiangiogenic agents. We aim to assess the impact of BM on prognosis, and the efficacy and safety of nivolumab in patients enrolled in the NIVOREN trial.All patients with BM at inclusion were included in our study. The primary endpoint was overall survival (OS). Secondary endpoints were progression-free survival (PFS), objective response rate (ORR), safety, and skeletal-related events (SRE).Among 720 patients treated with nivolumab, 194 presented BM at inclusion. The median follow-up was 23.9 months. Median OS was 17.9 months in patients with BM versus 26.1 months in patients without BM (p = 0.0023). The difference was not statistically significant after adjustment (p = 0.0707). The median PFS was shorter in patients with BM even after adjustment (2.8 versus 4.6 months, p = 0.0045), as well as the ORR (14.8% versus 23.3%). SRE occurred for 36% of patients with BM. A post-hoc analysis evaluating the impact of bone-targeting agents (BTA) on SRE incidence showed a significant benefit of BTA on the incidence of SRE (OR = 0.367, CI95% [0.151-0.895]).Nivolumab is associated with shorter PFS, and lower ORR in RCC patients with BM. Our study suggests that BTA in association with immunotherapy decreases the incidence of SRE." @default.
• W4316038761 created "2023-01-14" @default.
• W4316038761 creator A5003798935 @default.
• W4316038761 creator A5004989566 @default.
• W4316038761 creator A5019500272 @default.
• W4316038761 creator A5020353650 @default.
• W4316038761 creator A5021549650 @default.
• W4316038761 creator A5026262558 @default.
• W4316038761 creator A5028221013 @default.
• W4316038761 creator A5030902321 @default.
• W4316038761 creator A5031054777 @default.
• W4316038761 creator A5033431260 @default.
• W4316038761 creator A5035359860 @default.
• W4316038761 creator A5039277233 @default.
• W4316038761 creator A5042461515 @default.
• W4316038761 creator A5048784388 @default.
• W4316038761 creator A5049672639 @default.
• W4316038761 creator A5049724283 @default.
• W4316038761 creator A5056574716 @default.
• W4316038761 creator A5057183350 @default.
• W4316038761 creator A5059690857 @default.
• W4316038761 creator A5059810021 @default.
• W4316038761 creator A5063831527 @default.
• W4316038761 creator A5074162105 @default.
• W4316038761 creator A5076354847 @default.
• W4316038761 creator A5082227510 @default.
• W4316038761 creator A5082984172 @default.
• W4316038761 creator A5088916163 @default.
• W4316038761 creator A5090408060 @default.
• W4316038761 date "2023-03-01" @default.
• W4316038761 modified "2023-10-18" @default.
• W4316038761 title "Efficacy and safety of nivolumab in bone metastases from renal cell carcinoma: Results of the GETUG-AFU26-NIVOREN multicentre phase II study" @default.
• W4316038761 cites W1201824504 @default.
• W4316038761 cites W1967875617 @default.
• W4316038761 cites W1995341536 @default.
• W4316038761 cites W2055229817 @default.
• W4316038761 cites W2068420541 @default.
• W4316038761 cites W2080501071 @default.
• W4316038761 cites W2086066681 @default.
• W4316038761 cites W2086636804 @default.
• W4316038761 cites W2106315375 @default.
• W4316038761 cites W2111378135 @default.
• W4316038761 cites W2139860898 @default.
• W4316038761 cites W2151355131 @default.
• W4316038761 cites W2155688313 @default.
• W4316038761 cites W2222086386 @default.
• W4316038761 cites W2592144107 @default.
• W4316038761 cites W2593338436 @default.
• W4316038761 cites W2746203589 @default.
• W4316038761 cites W2889857576 @default.
• W4316038761 cites W2904455705 @default.
• W4316038761 cites W2912521988 @default.
• W4316038761 cites W3119005666 @default.
• W4316038761 cites W3212198841 @default.
• W4316038761 doi "https://doi.org/10.1016/j.ejca.2022.12.028" @default.
• W4316038761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36746010" @default.
• W4316038761 hasPublicationYear "2023" @default.
• W4316038761 type Work @default.
• W4316038761 citedByCount "2" @default.
• W4316038761 countsByYear W43160387612023 @default.
• W4316038761 crossrefType "journal-article" @default.
• W4316038761 hasAuthorship W4316038761A5003798935 @default.
• W4316038761 hasAuthorship W4316038761A5004989566 @default.
• W4316038761 hasAuthorship W4316038761A5019500272 @default.
• W4316038761 hasAuthorship W4316038761A5020353650 @default.
• W4316038761 hasAuthorship W4316038761A5021549650 @default.
• W4316038761 hasAuthorship W4316038761A5026262558 @default.
• W4316038761 hasAuthorship W4316038761A5028221013 @default.
• W4316038761 hasAuthorship W4316038761A5030902321 @default.
• W4316038761 hasAuthorship W4316038761A5031054777 @default.
• W4316038761 hasAuthorship W4316038761A5033431260 @default.
• W4316038761 hasAuthorship W4316038761A5035359860 @default.
• W4316038761 hasAuthorship W4316038761A5039277233 @default.
• W4316038761 hasAuthorship W4316038761A5042461515 @default.
• W4316038761 hasAuthorship W4316038761A5048784388 @default.
• W4316038761 hasAuthorship W4316038761A5049672639 @default.
• W4316038761 hasAuthorship W4316038761A5049724283 @default.
• W4316038761 hasAuthorship W4316038761A5056574716 @default.
• W4316038761 hasAuthorship W4316038761A5057183350 @default.
• W4316038761 hasAuthorship W4316038761A5059690857 @default.
• W4316038761 hasAuthorship W4316038761A5059810021 @default.
• W4316038761 hasAuthorship W4316038761A5063831527 @default.
• W4316038761 hasAuthorship W4316038761A5074162105 @default.
• W4316038761 hasAuthorship W4316038761A5076354847 @default.
• W4316038761 hasAuthorship W4316038761A5082227510 @default.
• W4316038761 hasAuthorship W4316038761A5082984172 @default.
• W4316038761 hasAuthorship W4316038761A5088916163 @default.
• W4316038761 hasAuthorship W4316038761A5090408060 @default.
• W4316038761 hasConcept C120665830 @default.
• W4316038761 hasConcept C121332964 @default.
• W4316038761 hasConcept C121608353 @default.
• W4316038761 hasConcept C126322002 @default.
• W4316038761 hasConcept C126894567 @default.
• W4316038761 hasConcept C141071460 @default.
• W4316038761 hasConcept C143998085 @default.
• W4316038761 hasConcept C203092338 @default.
• W4316038761 hasConcept C2777472916 @default.
• W4316038761 hasConcept C2777701055 @default.

• next